Indian pharma companies are increasingly relying on positioning themselves in niche or specialty areas to increase their revenues. Diabetes patients saw a revolution in insulin drugs last year, when Shreya Life Sciences launched the world’s first oral insulin under the brand name of 'Oral- Recosulin'. The company’s top brass already announced that it is bullish on specialty products.